VRTX News Alert Vertex Pharmaceuticals Inc (VRTX) 113.66 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:07 AM

Vertex Pharmaceuticals Inc (VRTX) 113.66 $VRTX

Vertex to Present at Upcoming Investor Conferences
Business Wire - Wed Feb 11, 3:05PM CST
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24th at 11:30 a.m. ET. Vertex will also present at the Cowen and Company Healthcare Conference in Boston, MA on Tuesday, March 3rd at 10:40 a.m. ET.
VRTX: 113.66 (+4.03)

Today's Review on Biotech Equities - Vertex Pharma, Alexion Pharma, Arrowhead Research, Medivation, and Incyte
PR Newswire - Tue Feb 10, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 104.71 (+0.67), VRTX: 113.66 (+4.03), ARWR: 6.77 (+0.21), INCY: 75.94 (+0.28), ALXN: 182.29 (+6.02)

Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)

Stock Market News for February 06, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 9:10AM CST
Rise in oil prices, new deals and upbeat quarterly results helped benchmarks settle in the green on Thursday
KMI: 41.97 (+0.21), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), MON: 124.77 (+2.00), FCX: 20.29 (+0.82), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), XOM: 93.37 (+1.00), COP: 69.88 (+1.84), SLB: 88.38 (+2.42), HSP: 87.35 (unch), AA: 15.81 (+0.16), EOG: 96.92 (+2.12), CVX: 112.78 (+1.92), DOW: 49.44 (+0.29)

Insider Trading Alert - DAN, VRTX And ENSG Traded By Insiders
at The Street - Thu Feb 05, 10:30AM CST
Stocks with insider trader activity include DAN, VRTX and ENSG
ENSG: 40.91 (+0.06), VRTX: 113.66 (+4.03), DAN: 22.96 (-0.04)

Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 04, 10:47AM CST
Earnings remained in focus last week with several big biotech names coming out with fourth quarter results and guidance for 2015.
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)

Vertex Should Expect Approvals For Its Cystic Fibrosis Medications
Clinically Sound Investor - at Seeking Alpha - Mon Feb 02, 8:16PM CST

VRTX: 113.66 (+4.03)

Super Bowl Stocks: Seattle's Best Vs. Boston Strong
at Investor's Business Daily - Sat Jan 31, 7:02AM CST
The New England Patriots behind quarterback Tom Brady are just barely favored to beat the top-rated defense of the Seattle Seahawks in Super Bowl XLIX on Sunday. But what stocks win in the battle between the best stocks in Washington and...
SBUX: 91.58 (-0.24), BIIB: 391.66 (-0.45), AMZN: 381.83 (+4.66), VRTX: 113.66 (+4.03), DNKN: 46.70 (-0.69), SAM: 303.26 (-0.97), MCD: 95.65 (+0.56), MSFT: 43.87 (+0.78)

Vertex Pharmaceuticals (VRTX) Downgraded From Hold to Sell
at The Street - Fri Jan 30, 3:40PM CST
Vertex Pharmaceuticals (VRTX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
VRTX: 113.66 (+4.03)

Is the 'January Effect' Signaling a Down Year for the Stock Market?
at The Street - Fri Jan 30, 2:14PM CST
CNBC's 'Fast Money Halftime' trading panel took a look at how stocks have shaped up for the first month of 2015 and what that means for the next 11 months.
AMZN: 381.83 (+4.66), BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), FEYE: 42.26 (+2.63), SHAK: 40.69 (+0.04), IBB: 323.46 (+3.04), EEQ: 37.09 (-0.36), TLT: 128.19 (-1.33), SPY: 209.78 (+0.86), SONC: 31.59 (-0.37), QQQ: 106.91 (+0.91), GILD: 101.90 (+1.10), CMG: 674.89 (+4.60), DIA: 180.34 (+0.50), MCD: 95.65 (+0.56), IWM: 121.53 (+0.72)

IBB Is +34% For 1 Year And +7.31% For 2015 - But What Are The Risks?
Reuben Sushman - at Seeking Alpha - Fri Jan 30, 9:07AM CST

VRTX: 113.66 (+4.03), Q: 63.31 (+0.06), IBB: 323.46 (+3.04), CELG: 115.88 (+0.16)

Vertex Pharmaceuticals Slumps: VRTX Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 7:52AM CST
Vertex Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 6% on the day.
VRTX: 113.66 (+4.03), OPHT: 51.11 (+0.12)

Vertex Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 5.87%
Comtex SmarTrend(R) - Thu Jan 29, 3:49PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.28 to a high of $115.94. Yesterday, the shares fell 5.9%, which took the trading range below the 3-day low of $120.88 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 113.66 (+4.03)

After Yesterday's Decline of 5.87%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Jan 29, 3:48PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.28 to a high of $115.94. Yesterday, the shares fell 5.9%, which took the trading range below the 3-day low of $120.88 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 113.66 (+4.03)

Alexion Beats Q4 Estimates, Appoints New CEO
at Investor's Business Daily - Thu Jan 29, 12:28PM CST
Big-cap biotech Alexion Pharmaceuticals (ALXN) beat Q4 estimates but reported lower than expected guidance Thursday as it announced a change of leadership. Vertex Pharmaceuticals (VRTX) and Celgene (CELG) also moved on new earnings reports. Alexion's...
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), ALXN: 182.29 (+6.02), CELG: 115.88 (+0.16)

Vertex Pharmaceutical (VRTX) Stock Declines Today Following Earnings Realease
at The Street - Thu Jan 29, 10:44AM CST
Vertex Pharmaceutical (VRTX) shares are falling today after the company reported a wider year over year quarterly loss and analysts' tepid response to the tone of its conference call
VRTX: 113.66 (+4.03)

Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 29, 9:10AM CST
Although Vertex's (VRTX) 4Q loss was wider-than-expected, revenues surpassed expectations.
BIIB: 391.66 (-0.45), VRTX: 113.66 (+4.03), ALXN: 182.29 (+6.02), CELG: 115.88 (+0.16)

Vertex Phamraceuticals (VRTX) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Thu Jan 29, 8:03AM CST
The following Vertex Phamraceuticals (VRTX) conference call took place on January 28, 2015, 05:00 PM ET. This is a transcript of that earnings call:
VRTX: 113.66 (+4.03)

Continued Expansion Into The Cystic Fibrosis Treatment Market Bodes Well For Vertex
Doug Van Cuyk - at Seeking Alpha - Thu Jan 29, 6:52AM CST

VRTX: 113.66 (+4.03)

Vertex Pharmaceuticals' (VRTX) CEO Jeffrey Leiden on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Jan 28, 10:36PM CST

VRTX: 113.66 (+4.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LINC Lawsuit: Boardroom Stumbles Spark Investor Action

Class Action Kickoff: Lincoln's Educational Curveball No one fancies home runs when the ball’s out of sight, and that’s probably how some investors in Lincoln Educational Services Corporation (NASDAQ: LINC) are feeling right now. A group of shareholders has pulled back the curtain on what they believe are more than just administrative hiccups—allegations of...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Venue Two Eleven: Historic Charm Meets Modern Events

Welcome To Venue Two Eleven: Where History Meets Modernity Alright, folks. Let’s talk about Venue Two Eleven—a new joint in town that’s blending the old with the new in a way that’s got me raising an eyebrow and maybe even sipping my coffee a little slower. Nestled in the Museum of the Oregon Territory, this place is pulling double duty as both a window to the...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Alaska LNG Project Boosted by Strategic Positioning

Alaska LNG: Right Place, Right Time Someone bring out the confetti, because Paul Sullivan, Co-Chairman of Gastech, is celebrating Alaska LNG like it's 1999. And for good reason. If Alaska ever played its cards right, now's the moment according to the industry veteran. After Gastech 2026 wrapped its events in Bangkok last month, Sullivan laid out why the stars are aligning...

U.S. Millionaire Surge: Market Waves or Mirage?

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Costa Rican Firms Chase Growth at SIAL Paris 2026

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

Spire's Year-End Call: Eyes on Earnings & Guidance

Anticipation Builds for Spire's Upcoming Earnings Call If you're keen on natural gas and the energy sector, keep a firm grip on your coffee cup because Spire Inc. (NYSE: SR) is about to spill the beans on their fiscal 2026 financials. Mark your calendars for November 17. Whether you're tuning in via phone or hitching a ride on the webcast, you're in for an earful. Time...

Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...